Making a difference with your help.
Protocol Name: Vonafexor Fixed Dose-escalation Safety and Proof-of-concept Study in Patients With at Risk of Progression Alport Syndrome Sponsor: Enyo Pharma Indication: Alport Syndrome Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Protocol Name: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living with Obesity Sponsor: Eli Lilly Indication: CVD and CKD Outcomes in patients with Obesity Principal Investigator:Bernard Fischbach, MD Location:Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >
Protocol Name: Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis Sponsor: River 3 Renal Indication: Alport Syndrome, Focal segmental glomerulosclerosis (FSGS) Primary Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Protocol Name: ACTION3: A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB Sponsor: Dimerix B Indication: FSGS Primary Investigator: Kim Rice, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Protocol Name: Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease Sponsor: Vertex Indication: APOL1-Mediated Proteinuric Kidney Disease Primary Investigator: Bernard Fischbach, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >